Alzinova succesfully completes project funded by innovation agency Vinnova
Alzinova’s vaccine ALZ-101, has successfully been evaluated in a novel species and via a novel route of administration. An assessment of systemic toxicological effects was also included.
The animal species chosen for this study responded well to vaccination already after two immunizations. The antibody titres were all comparable to those observed after repeated vaccinations of a transgenic mouse model, thus supporting both the chosen animal as a model and the novel route of administration evaluated in this project. No systemic toxicity was considered to be related to the test article, in accordance with previous vaccinations performed in mice.